Physician profile
Daniel S Choi
NPI 1760820633
$20,777.99
in general payments reported to CMS, 2019-2025
38 companies · $5,112 in 2025
The $5,112 reported for 2025 was more than what 91% of Cornea and External Diseases Specialist providers received nationally (typical 2025 total: $477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,942 · 2020: $802 · 2021: $2,044 · 2022: $6,070 · 2023: $3,100 · 2024: $1,709 · 2025: $5,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,909 · Consulting Fee: $1,688 · Travel and Lodging: $1,306 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,909.14 |
| Consulting Fee | $1,687.50 |
| Travel and Lodging | $1,306.26 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $6,161.51 | 2021-2025 | Kxl System (Not Refurbished), Kxl System, Idosetr |
| Alcon Vision LLC | $3,165.56 | 2019-2025 | Clareon, Rocklatan, Lensx |
| Sight Sciences, INC. | $1,593.45 | 2020-2025 | Omni Surgical System, Sion Surgical Instrument |
| Stryker Corporation | $1,377.65 | 2023-2025 | Mild Device Kit, Optablate, Spinejack |
| Kala Pharmaceuticals, INC. | $1,241.87 | 2021-2022 | |
| Aerie Pharmaceuticals, INC. | $1,050.19 | 2019-2021 | |
| Biotissue Holdings INC. | $601.23 | 2025 | |
| Abbvie INC. | $591.60 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Sun Pharmaceutical Industries INC. | $553.37 | 2019-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $448.79 | 2019-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $443.80 | 2019-2022 | |
| Painteq LLC | $362.30 | 2023-2024 | Painteq |
| Dompe US, INC. | $300.46 | 2019-2025 | Oxervate |
| Shire North American Group INC | $261.66 | 2019 | |
| Oyster Point Pharma, INC. | $247.31 | 2023-2025 | Tyrvaya, Ryzumvi |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $229.23 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $228.07 | 2019-2021 | |
| Medtronic, INC. | $202.86 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $192.80 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $192.43 | 2023-2025 | Vyzulta, Miebo |
| Avanos Medical | $188.12 | 2023-2025 | Coolief* Cooled Radiofrequency |
| New World Medical,INC. | $144.98 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $142.66 | 2019-2025 | Eylea Hd |
| Beaver-Visitec International, INC. | $131.62 | 2019-2025 | |
| Allergan, INC. | $114.10 | 2020-2022 | |
| Rxsight INC | $105.98 | 2024-2025 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Horizon Therapeutics Plc | $89.20 | 2022 | |
| Hoffmann-La Roche Limited | $81.20 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $60.41 | 2023 | Iovera |
| Eyevance Pharmaceuticals LLC | $45.52 | 2020 | |
| Amgen INC. | $44.70 | 2025 | Tepezza |
| Harrow Eye, LLC | $44.31 | 2025 | Verkazia, Natacyn, Flarex |
| Genentech USA, INC. | $29.73 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $26.14 | 2019 | |
| Boston Scientific Corporation | $24.15 | 2023 | Wavewriter Alpha Prime 16 |
| Medtronic USA, INC. | $21.80 | 2019 | |
| Rayner Intraocular Lenses Limited | $21.60 | 2022 | |
| Coopervision INC. | $15.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Choi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.